Bhavesh Ashar

CIK: 0001849740

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)1 (12.5%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)4 (50.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

TYRA

Tyra Biosciences, Inc.

Officer

SWTX

SpringWorks Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (8 total)

TYRA
Tyra Biosciences, Inc.
May 5, 2026
Award(A)
Direct
15K shares-
TYRA
Tyra Biosciences, Inc.
Dec 1, 2025
Award(A)
Stock Option (Right to Buy)
Direct
300K shares-
SWTX
SpringWorks Therapeutics, Inc.
Jul 1, 2025
Disposition(D)
Direct
62.1K shares-
SWTX
SpringWorks Therapeutics, Inc.
Feb 20, 2025
Sale(S)
Direct
1K shares at avg. $61.19$62K
SWTX
SpringWorks Therapeutics, Inc.
Jan 10, 2025
Award(A)
Direct
17.3K shares-
SWTX
SpringWorks Therapeutics, Inc.
Jan 6, 2025
Tax Payment(F)
Direct
2.3K shares at avg. $38.86$89K
SWTX
SpringWorks Therapeutics, Inc.
Jan 5, 2025
Tax Payment(F)
Direct
3.8K shares at avg. $38.19$146K
SWTX
SpringWorks Therapeutics, Inc.
Jan 4, 2025
Tax Payment(F)
Direct
4.5K shares at avg. $38.19$171K

		Type	Shares	Price		Ownership
May 5, 2026	TYRA Tyra Biosciences, Inc.	Award(A)	15,013	-	$0	Direct
Dec 1, 2025	TYRA Tyra Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	300,000	-	-	Direct
Jul 1, 2025	SWTX SpringWorks Therapeutics, Inc.	Disposition(D)	62,053	-	-	Direct
Feb 20, 2025	SWTX SpringWorks Therapeutics, Inc.	Sale(S)	1,016	$61.19	$62,168	Direct
Jan 10, 2025	SWTX SpringWorks Therapeutics, Inc.	Award(A)	17,323	-	$0	Direct
Jan 6, 2025	SWTX SpringWorks Therapeutics, Inc.	Tax Payment(F)	2,284	$38.86	$88,756	Direct
Jan 5, 2025	SWTX SpringWorks Therapeutics, Inc.	Tax Payment(F)	3,825	$38.19	$146,077	Direct
Jan 4, 2025	SWTX SpringWorks Therapeutics, Inc.	Tax Payment(F)	4,475	$38.19	$170,900	Direct

1-8 of 8 transactions

About Ashar Bhavesh

Ashar Bhavesh (SEC CIK 0001849740) files insider reports with the SEC as Chief Operating Officer of Tyra Biosciences, Inc. (TYRA) and Chief Commercial Officer of SpringWorks Therapeutics, Inc. (SWTX).

Signal8 holds 7 ownership filings by Ashar Bhavesh (1 Form 3, 6 Form 4), filed between Jan 7, 2025 and May 7, 2026. Those filings report 8 transactions, from Jan 4, 2025 to May 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ashar Bhavesh's filings is in STAMFORD, CT.

Recent filings by Ashar Bhavesh

May 5, 2026: Grant or award of TYRA shares (Form 4, code A).
Dec 1, 2025: Grant or award of TYRA derivative securities (Form 4, code A).
Jul 1, 2025: Disposition to issuer transaction of SWTX shares (Form 4, code D).
Feb 20, 2025: Open-market sale of SWTX shares (Form 4, code S).
Jan 10, 2025: Grant or award of SWTX shares (Form 4, code A).

Other insiders filing for Tyra Biosciences, Inc. (TYRA)

Harris Todd, President and CEO
Rueb Yuliya, Vice President, Finance (PAO)
Fuhrman Alan, Chief Financial Officer
RA CAPITAL MANAGEMENT, L.P., Director
Verjee Rehan, Director
Moran Susan, Director

How to read Form 4 transaction codes